The effect of the dose of carvedilol on cardiac sympathetic nerve activity (CSA) and mortality remain uncertain in patients with chronic heart failure (CHF).
he β-blockers improve cardiac function and prolong survival in patients with systolic chronic heart failure (CHF). [1] [2] [3] [4] In the Multicenter Oral Carvedilol Heart Failure Assessment (MOCHA) trial, carvedilol (6.25-25 mg/day) was associated with dose-related improvements in left ventricular (LV) function and survival in heart failure (HF) patients in a population that was 77% Caucasian. 5 However, the response to carvedilol may vary among different ethnic groups [6] [7] [8] [9] and indeed, the dose of carvedilol for treatment in Japanese is 10-20 mg/day, which is less than half of the dose used in Western patients. 10, 11 In the Multicenter Carvedilol Heart Failure Dose Assessment (MUCHA) trial, low-dose carvedilol (5 mg/day group or 20 mg/day group) improved the LV ejection fraction (LVEF) and reduced cardiovascular hospitalization in Japanese patients with CHF. 12 In addition, carvedilol therapy achieved a dose-related improvement in CHF and LVEF; cardiovascular hospitalization was markedly reduced. However, the relationship between the dose-dependent improvement of carvedilol and prognosis in Japanese patients with CHF remains unknown.
Cardiac sympathetic nerve activity (CSA) plays an important role in the pathophysiology of CHF. [13] [14] [15] [16] [17] We previously reported that CSA plays an important role in the pathophysiology of CHF, independent of hemodynamic overload, and that the transcardiac gradient of norepinephrine (NE) is a more reliable biomarker of CSA than the peripheral venous NE level. 18, 19 Moreover, carvedilol treatment has been reported as associated with a significant reduction in the transcardiac gradient of NE, without any changes in the plasma arterial NE, in patients with CHF. 20 There has not previously been a study correlating the transcardiac gradient of NE, brain natriuretic peptide (BNP) and N-terminal BNP (NT-proBNP) with the dose of carvedilol. In the present study, we investigated the relationship of these parameters with the prognosis of CHF in the same population.
Methods

Patients
Consecutive symptomatic CHF patients undergoing cardiac catheterization were included (the same study population as in our previously reported study of 356 patients 19 ). Patients with acute myocardial infarction, angina pectoris, congenital heart disease or pacemaker implantation, and those on dialysis therapy were excluded.
There were 116 patients with systolic CHF (LVEF <45%) who received carvedilol, starting with a dose of 1.25-5 mg/day and then increased to the final target dose of 20 mg/day, depending on its tolerance by each patient (carvedilol was not tolerated by 9 patients (7.7%), and was discontinued during the follow-up period). Finally, 107 patients were enrolled and divided into 2 groups [group I: low dose (<10 mg/day, n=41) and group II: high dose (≥10 mg/day, n=66)]. New York Heart Association (NYHA) functional class was evaluated on the day of cardiac catheterization. Informed consent was given by all patients before participation in the study, following protocol approval by the institutional Committee on Human Investigation.
Study Protocol
All patients were premeditated with an oral dose of diazepam (5 mg) and rested in bed while supine for at least 20 min. Left-sided cardiac catheterization was performed and blood pressure was measured. Heart rate was monitored by ECG.
Blood samples for measurement of plasma NE, BNP and NT-proBNP were collected simultaneously from the aortic root (AO) and coronary sinus (CS). A 6Fr catheter for blood sampling was positioned in the CS, and the position of the catheter was confirmed as previously reported. 19 Blood samples for the measurement of creatinine were also collected from the AO. Left ventriculography was performed using contrast medium or radioisotope before or at least 1 week after the hemodynamic measurements and blood sampling. Renal function was represented by the estimated glomerular filtration rate according to the Cockcroft-Gault equation. 21 
Measurement of NE, BNP and NT-ProBNP Concentrations
Samples for the assay of plasma BNP and NT-proBNP concentrations were transferred to chilled disposable tubes containing aprotinin (500 kallikrein inactivator units/ml). The blood samples were immediately placed on ice and centrifuged at 4°C, and the plasma was frozen in aliquots and stored at −30°C until assay. Plasma BNP concentrations were measured by an automated chemiluminescent enzyme immunoassay analyzer exclusive kit (Shionogi, Japan). 22 Plasma concentrations of NT-proBNP were measured using an automated Elecsys proBNP sandwich immunoassay (Roche Diagnostics) as previously reported. 23 Plasma NE concentrations were measured by high-performance liquid chromatography as reported previously. 22 
Statistical Analysis
All results are expressed as the mean ± SD. The chi-square test was used to determine differences between groups. Univariate analyses were performed using Student's t-test. Log BNP and log NT-proBNP were used for regression models. In the multivariate Cox proportional hazard analyses, the main models were adjusted for age, sex, and variables considered to reflect the severity of CHF at baseline and those associated with mortality in the univariate analyses at the P< 0.10 level. Multivariate Cox proportional hazard analyses were performed as stepwise regressions with backward elimination. Kaplan-Meier analysis was performed on the cumulative rates of survival in patients with CHF stratified into 2 groups on the basis of the median dose of carvedilol, and the differences between survival curves were analyzed by log-rank test. A value of P<0.05 was considered significant. Table 1 summarizes the patients' characteristics according to the dose of carvedilol. The cause of systolic CHF was ischemic heart disease (IHD) in 54, dilated cardiomyopathy (DCM) in 33 and hypertensive heart disease (HHD) in 20 patients. There were 73 patients in NYHA functional class I or II, and 34 in class III or IV. At entry to the study, most patients were already receiving the standard oral therapy. The mean dose of carvedilol was 9.65±5.6 mg/day and mean duration of carvedilol treatment was 12.2 months. During a median follow-up of 4.3 years, 13 patients died: 10 in the low-dose group and 3 in the high-dose group (P=0.001). There was no difference between 2 groups in mean blood pressure, LVEF, LV end-diastolic pressure and plasma NE in the AO (Figure 1) . Plasma BNP, NT-proBNP in the AO, transcardiac gradient of NE and heart rate were significantly higher in the low-dose group than the high-dose group (Figure 1 ).
Results
Patient Characteristics
Univariate and Multivariate Predictors of Mortality: Comparison of Hemodynamic Parameters and Neurohumoral Factors
We analyzed 13 clinical, neurohumoral and hemodynamic variables using univariate and stepwise multivariate Cox proportional hazards regression analyses ( Table 2 ). In the stepwise multivariate analyses, a high level of transcardiac increase in NE (P<0.001), high level of plasma log NTproBNP (P=0.004) and low dose of carvedilol (<10 mg/day) (P=0.012) were significant independent predictors.
Kaplan-Meier Lifetime Analysis
The patients were divided into 2 groups according to the median dose of carvedilol (10 mg/day), and cumulative survival curves were constructed according to KaplanMeier survival methods. The hazard ratio of the low-dose carvedilol group (<10 mg/day) was 6.5 (95% confidence interval, 1.07-40.8) compared with that of the high-dose carvedilol group (≥10 mg/day) based on mortality (P=0.012) (Figure 2) .
Relationship Between the Carvedilol Dose and Transcardiac Gradient of NE and Plasma NE Concentration
The carvedilol dose did not correlate with plasma NE concentration (r=0.108, P=0.69), but it significantly correlated with the transcardiac gradient of NE (r=−0287, P=0.0032) (Figure 3) .
Discussion
In the present study, there was a significant relationship between the dose of carvedilol and the transcardiac gradient of NE, a biomarker of CSA. Moreover, the dose of carvedilol was an independent and useful predictor of the prognosis in patients with systolic CHF who received standard therapy including carvedilol. Therefore, the beneficial effects of carvedilol therapy on cardiac mortality are associated with the effects of carvedilol on CSA, which may be influenced by the dose.
In the MOCHA trial, 5 carvedilol was possibly associated with dose-related improvements in LV function and survival in HF patients. In the present study, a high-dose of carvedilol was an independent and useful prognostic predictor in CHF patients. Furthermore, the hazard ratio for mortality in the low-dose carvedilol group was 6.5 compared with the high-dose carvedilol group. In terms of the global improvement in HF, LVEF, and morbidity, the recommended dose of carvedilol for Japanese patients with CHF ranges from 5 to 20 mg/day. 12 Based on our findings, the recommended dose of carvedilol may be more than 10 mg/day, if tolerated.
In Western countries, HF guidelines recommend that β-blockers be titrated to achieve the target dose (ie, carvedilol =50 mg/day) shown to be effective in major clinical trials, if tolerated. 24, 25 However, in the Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients With Heart Failure (OPTIMIZE-HF), Fonarow et al 26 reported that for more than two-thirds of patients the β-blocker dose was unchanged in the first 60-90 days after hospital discharge. Furthermore, at the 60-90-day post discharge followup, only 17.5% and 7.9% of patients, were being treated with the recommended target doses of carvedilol and metoprolol succinate, respectively. That finding demonstrates that the doses of β-blockers being prescribed in clinical practice are substantially less than the doses achieved in randomized clinical trials of HF and recommended in national guidelines.
In Japan, the daily dose of carvedilol for the treatment of HF is 5-20 mg, which is less than half of that used in Western countries. In the present study, the mean maintenance dose was 9.65±5.6 mg/day. Further, almost none of the patients had received up-titration of the carvedilol dose more than 3 months after discharge. In fact, it is not easy for a patient with HF to receive a β-blocker at the highest tolerated daily dose, because there is a risk of cardiac decompensation during up-titration of therapy in certain patients. 2, 3, 27 Although it was not easy to evaluate tolerability, our findings suggest that the ability of a patient to tolerate carvedilol at a dose greater than 10 mg provides important prognostic information. Judging from the Kaplan-Meier survival curves (Figure 2) , physicians should consider up-titration of carvedilol dosing (>10 mg) after discharge of systolic CHF patients, because the survival curves of the 2 groups clearly separated after several years (Figure 2) .
Study Limitations
First, the maintenance dose of carvedilol was not randomized in the present study. Second, we did not measure coronary blood flow. Third, the myocardial or interstitial NE concentration, which is a rational biomarker of CSA, cannot be estimated simply from the transcardiac increase in NE and coronary blood flow. 28, 29 Further studies are needed to compare the prognostic value of the transcardiac increase in NE with cardiac NE spillover, which can be evaluated by the radiotracer method and by measuring CS blood flow. The present study was a substudy of a previous study, 19 so the small numbers of patients and deaths are limitations for stepwise regression analysis including 13 variables. A future large-scale study is necessary to evaluate the effect of dose during long-term carvedilol therapy on survival of Japanese patients with CHF. Therefore, we look forward to the result of the ongoing Assessment of Beta-Blocker Treatment in Japanese Patients with Chronic Heart Failure (J-CHF) study.
In conclusion, higher doses of carvedilol caused a doserelated decrease in the transcardiac increase in NE, suggesting that the dose of carvedilol is important for management of CSA and prognosis in patients with systolic CHF.
